Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorChi, Kim
dc.contributor.authorBarnicle, Alan
dc.contributor.authorsibilla, caroline
dc.contributor.authorLai, Zhongwu
dc.contributor.authorCorcoran, Claire
dc.contributor.authorBarrett, Carl
dc.contributor.authorMateo, Joaquin
dc.date.accessioned2023-05-11T07:14:03Z
dc.date.available2023-05-11T07:14:03Z
dc.date.issued2023-01-04
dc.identifier.citationChi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, et al. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res. 2023 Jan 4;29(1):81–91.
dc.identifier.issn1557-3265
dc.identifier.urihttps://hdl.handle.net/11351/9507
dc.descriptionADN tumoral circulant; Càncer de pròstata
dc.description.sponsorshipThis study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp.
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.relation.ispartofseriesClinical Cancer Research;29(1)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCèl·lules canceroses
dc.subjectMedicaments antineoplàstics
dc.subjectPròstata - Càncer
dc.subject.meshProstatic Neoplasms, Castration-Resistant
dc.subject.meshCirculating Tumor DNA
dc.subject.meshAntineoplastic Agents
dc.titleDetection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1158/1078-0432.CCR-22-0931
dc.subject.decsneoplasias prostáticas resistentes a la castración
dc.subject.decsADN tumoral circulante
dc.subject.decsantineoplásicos
dc.relation.publishversionhttps://doi.org/10.1158/1078-0432.CCR-22-0931
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Chi KN] BC Cancer Agency, Vancouver, Canada. [Barnicle A] Translational Medicine, AstraZeneca, Cambridge, United Kingdom. [Sibilla C, Corcoran C] Precision Medicine and Biosamples, AstraZeneca, Cambridge, United Kingdom. [Lai Z, Barrett JC] Translational Medicine, AstraZeneca, Waltham, Massachusetts. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid36043882
dc.identifier.wos000907928500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple